Modulation of fatty acids oxidation in heart failure by selective pharmacological inhibition of 3-ketoacyl coenzyme-A thiolase

Current Clinical Pharmacology

Volumn 2, Issue 3, 2007, Pages 190-196

  Fragasso, Gabriele ^a   Spoladore, Roberto ^a   Cuko, Amarild ^a   Palloshi, Altin ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

3 ketoacyl coenzyme A thiolase inhibitors; Diabetes; Heart failure; Left ventricular function; Ranolazine; Trimetazidine

Indexed keywords

ACETYL COENZYME A ACYLTRANSFERASE; ACYLTRANSFERASE INHIBITOR; ADENOSINE TRIPHOSPHATE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARNITINE PALMITOYLTRANSFERASE INHIBITOR; CARVEDILOL; CREATINE PHOSPHATE; DIGOXIN; DIURETIC AGENT; DOBUTAMINE; ENDOTHELIN 1; ETOMOXIR; FATTY ACID; GLUCOSE; HEMOGLOBIN A1C; INSULIN; OXFENICINE; PERHEXILINE; PLACEBO; RANOLAZINE; TRIACYLGLYCEROL; TRIMETAZIDINE;

ADD ON THERAPY; ANGINA PECTORIS; CARDIOMYOPATHY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CORONARY STENT; DISEASE ASSOCIATION; DOG; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; ENDOTHELIAL DYSFUNCTION; ENERGY METABOLISM; ENZYME INHIBITION; FATTY ACID METABOLISM; FATTY ACID OXIDATION; FOLLOW UP; GLUCOSE METABOLISM; GLUCOSE UTILIZATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; IN-STENT RESTENOSIS; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIVER DISEASE; MEDICAL RESEARCH; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PERIPHERAL NEUROPATHY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

ACETYL-COA C-ACYLTRANSFERASE; ANIMALS; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; FATTY ACIDS; GLUCOSE; HEART FAILURE; HUMANS; MYOCARDIAL ISCHEMIA; OXIDATION-REDUCTION; VENTRICULAR DYSFUNCTION, LEFT;

EID: 34948849728     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488407781668776     Document Type: Review

References (70)

1. Neely JR, Rovetto MJ, Oram JF. Myocardial utilization of carbohydrate and lipids. Progr Cardiovasc Dis 1972; 15: 289-329.
2. Lommi J, Kupari M, Koskinen P, et al. Blood ketone bodies in congestive heart failure. J Am Coll Cardiol 1996; 28: 665-72.
3. Riley M, Bell N, Elborn JS, Stanford CF, Buchanan KD, Nicholls DP. Metabolic response to graded exercise in chronic heart failure. Eur Heart J 1993; 14: 1484-8.
4. Paolisso G, De Riu S, Marrazzo G, Verza M, Varricchio M, D'Onofrio F. Insulin resistance and hyperinsulinemia in patients with chronic heart failure. Metabolism 1991; 40: 972-7.
5. Mc Veigh JJ, Lopaschuck GD. Dichloroacetate stimulation of glucose oxidation improves recovery of ischemic rat hearts. Am J Physiol 1990; 259: H1070-H1085.
6. Nicholl TA, Lopaschuck GD, McNeill GH. Effects of free fatty acids and dichloroacetate on isolated working diabetic rat hearts. Am J Physiol 1991; 261: H1053-9.
7. Bersin RM, Wolfe C, Kwasman M, et al. Improved hemodynamic function and mechanical efficiency in congestive heart failure with sodium dichloroacetate. J Am Coll Cardiol 1994; 23: 1617-24.
8. Fantini E, Demaison L, Sentex E, Grynberg A, Athias P. Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation. J Mol Cell Cardiol 1994; 26: 949-958.
9. Kantor PF, Lucien A, Kozak R, Lopashuck GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000; 86: 580-88.
10. Lopaschuk GD, Barr R, Thomas PD, Dyck JR. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2003; 93: e26-32.
11. MacInness A, Fairman DA, Binding P, et al. The antianginal trimetazidine does not exert its functional benefit via inhibition of mithocondrial longchain 3-ketoacyl coenzyme A thiolase. Circ Res 2003; 93: e33-7.
12. Antzelevitch C, Belardinelli L, Zygmunt AC, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004; 110: 904-910
13. Lopaschuck GD, Stanley WC. Glucose metabolism in the ischemic heart. Circulation 1997; 95: 313-5.
14. Nuutila P, Knuuti MJ, Raitakari M, et al. Effect of antilipolysis on heart and skeletal muscle glucose uptake in overnight fasted human. Am J Physiol 1994; 267: E941-E946.
15. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 2002; 23: 201-29.
16. Steinberg HO, Baron AD. Vascular function, insulin resistance and fatty acids. Diabetologia 2002; 45: 623-34.
17. Brottier L, Barat JL, Combe C, Boussens B, Bonnet J, Bricaud H. Therapeutic value of a cardioprotective agent in patients with severe ischemic cardiomyopathy. Eur Heart J 1990; 11: 207-212.
18. Lu C, Dabrowski P, Fragasso G, Chierchia SL. Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease. Am J Cardiol 1998; 82: 898-901.
19. Belardinelli R, Purcaro A. Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy. Eur Heart J 2001; 22: 2164-70.
20. Fragasso G, Piatti PM, Monti L, et al. Short and long term beneficial effects of partial free fatty acid inhibition in diabetic patients with ischemic dilated cardiomyopathy. Am Heart J 2003; 146: E1-8.
21. Rosano GMC, Vitale C, Sposato B, et al. Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study. Cardiovasc Diabetol 2003; 2: 16/1-16/9.
22. Vitale C, Wajngaten M, Sposato B, et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J 2004; 15: 1814-21.
23. Di Napoli P, Taccardi AA, Barsotti A. Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process ia patients with ischaemic dilated cardiomyopathy. Heart 2005; 91: 161-5.
24. 31P-NMR spectroscopy in the isolated rat heart. Arch Int Pharmacodyn Ther 1987; 286: 97-110.
25. 31P magnetic resonance spectroscopy. Lancet 1991; 338: 973-6.
26. 31P magnetic resonance spectroscopy. Circulation 1995; 92: 15-23.
27. Nascimben L, Ingwall JS, Pauletto P, et al. The creatine kinase system in failing and nonfailing human myocardium. Circulation 1996; 94: 1894-901.
28. Fragasso G, De Cobelli F, Perseghin G, et al. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J 2006; 27: 942-8.
29. Neubauer S, Horn M, Cramer M, et al. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 1997; 96: 2190-6.
30. Fragasso G, Palloshi A, Puccetti P, et al. A randomized clinical trial of trimetazidine, a partial five fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol 2006; 48: 992-8.
31. Sabbah HN, Chandler MP, Mishima T, et al. Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure. J Card Fail 2002; 8: 416-422.
32. Chandler MP, Stanley WC, Morita H, et al. Short-term treatment with ranolazine improves mechanical efficacy in dogs with chronic heart failure. Circ Res 2002; 91: 278-280.
33. Hayashida W, van Eyll C, Rousseau MF, Pouleur H. Effects of ranolazine on left ventricular regional diastolic function in patients with ischemic heart disease. Cardiovasc Drugs Ther 1994; 5: 741-747.
34. Aaker A, McCormack JG, Hirai T, Musch TI. Effects of ranolazine on the exercise capacity of rats with chronic heart failure induced by myocardial infarction. J Cardiovasc Pharmacol 1996; 28: 353-362.
35. McCormack JG, Baracos VE, Barr R, Lopaschuk GD. Effects of ranolazine on oxidative substrate preference in epitrochlearis muscle. J Appl Physiol 1996; 81: 905-910.
36. Murray AJ, Anderson RE, Watson GC, Radda GK, Clarke K. Uncoupling proteins in human heart. Lancet 2004; 364: 1786-8.
37. Opie LH. The metabolic vicious circle in heart failure. Lancet 2004; 364: 1733-4.
38. Piatti PM, Monti LD, Galli L, et al. Relationship between endothelin-1 concentrations and the metabolic alterations typical of the insulin resistance syndrome. Metabolism 2000; 49: 748-52.
39. Piatti PM, Monti LD, Zavaroni I, et al. Alterations in nitric oxide/cyclic-GMP pathway in nondiabetic siblings of patients with type 2 diabetes J Clin Endocrinol Metab 2000; 85: 2416-20.
40. Crettaz M, Zaninetti D, Jeanrenaud B. Insulin-resistance in heart and skeletal muscles of genetically obese Zucker rats. Biochem Soc Trans 1981; 9: 524-5.
41. Natali A, Taddei S, Quiñones Galvan A, et al. Insulin sensitivity, vascular reactivity, and clamp-induced vasodilatation in essential hypertension. Circulation. 1997; 96: 725-6.
42. Despres JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952-7.
43. Yoshimura T, Hisatomi A, Kajihara S, et al. The relationship between insulin resistance and polymorphisms of the endothelial nitric oxide synthase gene in patients with coronary artery disease. J Atheroscler Thromb 2003; 10: 43-7.
44. Piatti PM, Fragasso G, Monti LD, et al. Endothelial and metabolic characteristics of patients with angina and angiographically normal coronary arteries. J Am Coll Cardiol 1999; 34: 1452-60.
45. Piatti P, Di Mario C, Monti LD, et al. Association of insulin resistance, hyperleptinemia, and impaired nitric oxide release with instent restenosis in patients undergoing coronary stenting. Circulation 2003; 108: 2074-81.
46. The Decode Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999; 354: 617-21.
47. Wallhaus TR, Taylor M, DeGrado TR, Russell DC. Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. Circulation 2001; 103: 2441-6.
48. Cano C, Bermúdez VJ, Medina MT, et al. Trimetazidine diminishes fasting glucose in rats with fasting hyperglycemia: a preliminary study. Am J Ther 2003; 10: 444-6.
49. Monti LD, Setola E, Fragasso G, et al. Metabolic and endothelial effects of trimetazidine on forearm muscle in patients with type 2 diabetes and ischemic cardiomyopathy. Am J Physiol Endocrinol Metab 2006; 290: E54-E59.
50. Fragasso G, Piatti P, Monti L, et al. Acute effects of heparin administration on the ischemic threshold of patients with coronary artery disease: evaluation of the protective role of the metabolic modulator trimetazidine. J Am Coll Cardiol 2002; 39: 413-9.
51. Yamauchi-Kohno R, Miyauchi T, Hoshino T, et al. Role of endothelin in deterioration of heart failure due to cardiomyopathy in hamsters: increase in endothelin production in the heart and beneficial effect of endothelin A antagonist on survival and cardiac function. Circulation 1999; 99: 2171-6.
52. Maridonneau-Parini I, Harpey C. Effects of trimetazidine on membrane damage induced by oxygen free radicals in human red cells. Br J Clin Pharmacol 1985; 20: 148-151.
53. Chaitman BR, Pepine CJ, Parker JO, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 2004; 291: 309-316.
54. 1c in patients with chronic angina and diabetes. Eur Heart J 2006; 27: 42-48.
55. Lopashuck GD, Wall SR, Olley PM, Davies NJ. Etomoxir, a carnitine palmitoyltransferase I inhibitor, protects hearts from fatty acid-induced ischemic injury independent of changes in long chain acylcarnitine. Circ Res 1988; 63: 1036-43.
56. Ratheiser K, Schneeweiss B, Waldhausl W, et al. Inhibition by etomoxir of carnitine palmitoyltransferase I reduces hepatic glucose production and plasma lipids in non-insulin-dependent diabetes mellitus. Metabolism 1991; 40: 1185-90.
57. Turcani M, Rupp H. Etomoxir improves left ventricular performance of pressure-overloaded rat heart. Circulation 1997; 96: 3681-6.
58. Zarain-Herzberg A, Rupp H. Therapeutic potential of CPT I inhibitors: cardiac gene transcription as a target. Expert Opin Investig Drugs 2002; 11: 345-56.
59. Schmidt-Schweda S, Holubarsch C. First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin Sci 2000; 99: 27-35.
60. Schmitz FJ, Rösen P, Reinauer H. Improvement of myocardial function and metabolism in diabetic rats by the carnitine palmitoyl transferase inhibitor etomoxir. Horm Metab Res 1995; 27: 515-522.
61. Cabreros A, Merlos M, Laguna JC, Carrera MV. Down-regulation of acyl-CoA oxidase gene expression and increased NF-kappaB activity in etomoxir-induced cardiac hypertrophy. J Lipid Res 2003; 44: 388-98.
62. Merril CL, Ni H, Yoon LW, et al. Etomoxir-induced oxidative stress in HepG2 cells detected by differential gene expression is confirmed biochemically. Toxicol Sci 2002; 68: 93-101.
63. Kennedy JA, Kiosoglus AJ, Murphy GA, Pelle MA, Horowitz JD. Effect of perhexilline and oxfenicine on myocardial function and metabolism during low flow ischemia/reperfusion in the isolated rat heart. J Cardiovasc Pharmacol 2000; 36: 794-801.
64. Jeffrey FM, Alvarez L, Diczku V, Sherry AD, Mallory CR. Direct evidence that perhexiline modifies myocardial substrate utilization from fatty acids to lactate. J Cardiovasc Pharmacol 1995; 25: 469-72.
65. Stephens TW, Higgins AJ, Cook GA, Harris RA. Two mechanisms produce tissue-specific inhibition of fatty acid oxidation by oxfenicine. Biochem J 1985; 227: 651-60.
66. Bergman G, Atkinson L, Metcalfe J, Jackson J, Jewitt DE. Beneficial effect of enhanced myocardial carbohydrate utilisation after oxfenicine (L-hydroxyphenylglycine) in angina pectoris. Eur Heart J 1980; 1: 247-53.
67. Cole PL, Beamer AD, McGowan N, et al. Efficacy and safety of perhexiline maleate in refractory angina: a double-blind placebo-controlled clinical trial of a novel antianginal agent. Circulation 1990; 81: 1260-1270.
68. Lee L, Campbell R, Scheuermann-Freestone M, et al. Metabolic modulation with perhexiline in chronic heart failure. A randomized, controlled trial of short-term use of a novel treatment. Circulation 2005; 112: 3280-3288.
69. Meier C, Wahllaender A, Hess CW, Preisig R. Perhexiline-induced lipidosis in the dark Agouti (DA) rat: an animal model of genetically determined neurotoxicity. Brain 1986; 109: 649-660.
70. Killalea SM, Krum H. Systematic review of the efficacy and safety of perhexiline in the treatment of ischemic heart disease. Am J Cardiovasc Drugs 2001; 1: 193-204.